Pediatric Nephrology

, Volume 29, Issue 9, pp 1493–1505 | Cite as

Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease

  • Bradley A. Warady
  • Douglas M. SilversteinEmail author


Anemia management is an important component of the care provided to children with chronic kidney disease (CKD) and influences both morbidity and mortality risk. The introduction of recombinant human erythropoietin to the treatment regimen three decades ago revolutionized the therapy and significantly decreased the need for repeated blood transfusions and exposure to associated risks. Recent data on the efficacy and complications associated with erythropoietic-stimulating agent (ESA) usage has, however, prompted a reassessment of treatment-related recommendations. This review will address these recommendations, in addition to describing pediatric outcomes associated with current ESAs and presenting information on alternative ESAs, many of which will likely soon be incorporated into clinical practice.


Anemia Erythropoietin Hemoglobin Biosimilar 



The viewpoints of Douglas M. Silverstein are based on personal professional experience and are not intended to reflect the opinions and viewpoints of the United States Food and Drug Administration.


  1. 1.
    Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards & Quality (2005) 2005 Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Baltimore, MarylandGoogle Scholar
  2. 2.
    Staples AO, Wong CS, Smith JM, Gipson DS, Filler G, Warady BA, Martz K, Greenbaum LA (2008) Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol 4:48–56PubMedGoogle Scholar
  3. 3.
    Atkinson MA, Martz K, Warady BA, Neu AM (2010) Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol 25:1699–1706PubMedGoogle Scholar
  4. 4.
    Wong H, Mylrea K, Feber J, Drukker A, Filler G (2006) Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int 70:585–590PubMedGoogle Scholar
  5. 5.
    McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW (1984) Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 25:437–444PubMedGoogle Scholar
  6. 6.
    Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316:73–78PubMedGoogle Scholar
  7. 7.
    Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int 2:279–335Google Scholar
  8. 8.
    National Kidney Foundation (2006) K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47:S1–S146Google Scholar
  9. 9.
    World Health Organization (2008) de Benoist B, McLean E, Egli I and Cogswell M (eds) Worldwide Prevalence of Anaemia 1993–2005; WHO Global Database on Anaemia (available at
  10. 10.
    Nangaku M, Eckardt KU (2006) Pathogenesis of renal anemia. Semin Nephrol 26:261–268PubMedGoogle Scholar
  11. 11.
    Atkinson MA, Furth SL (2011) Anemia in children with chronic kidney disease. Nat Rev Nephrol 7:635–641PubMedGoogle Scholar
  12. 12.
    Atkinson MA, Pierce CB, Zack RM, Barletta GM, Yadin O, Mentser M, Warady BA, Furth SL (2010) Hemoglobin differences by race in children with CKD. Am J Kidney Dis 55:1009–1017PubMedCentralPubMedGoogle Scholar
  13. 13.
    Donnelly S (2001) Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis 38:415–425PubMedGoogle Scholar
  14. 14.
    Asada N, Takase M, Nakamura J, Oguchi A, Asada M, Suzuki N, Yamamura K-I, Nagoshi N, Shibata S, Rao TN, Fehling HJ, Fukatsu A, Minegishi N, Kita T, Kimura T, Okano H, Yamamoto M, Yanagita M (2011) Dysfunction of fibroblasta of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 121:3981–3990PubMedCentralPubMedGoogle Scholar
  15. 15.
    Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, Daniels SR (2006) Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. J Pediatr 149:671–675PubMedGoogle Scholar
  16. 16.
    Mitsnefes M, Flynn J, Cole S, Samuels J, Blydt-Hansen T, Saland J, Kimball T, Furth S, Warady B, CKiD Study Group (2010) Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 21:137–144PubMedCentralPubMedGoogle Scholar
  17. 17.
    Schaefer F (2008) Cardiac disease in children with mild-to moderate chronic kidney disease. Curr Opin Nephrol Hypertens 17:292–297PubMedGoogle Scholar
  18. 18.
    Gerson A, Hwang W, Fiorenza J, Barth K, Kaskel F, Weiss L, Zelikovsky N, Fivush B, Furth S (2004) Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 44:1017–1023PubMedGoogle Scholar
  19. 19.
    Borzych-Buzalka D, Bilginer Y, Ha IS, Bak M, Rees L, Cano F, Munarriz RL, Chua A, Pesle S, Emre S, Urzykowska A, Quiroz L, Ruscasso JD, White C, Pape L, Ramela V, Printza N, Vogel A, Kuzmanovska D, Simkova E, Muller-Wiefel DE, Sander A, Warady BA, Schaefer F, International Pediatric Peritoneal Dialysis Network (IPPN) Registry (2013) Management of anemia in children receiving chronic peritoneal dialysis. J Am Soc Nephrol 24:665–676Google Scholar
  20. 20.
    Furth SL, Cole SR, Fadrowski JJ, Gerson A, Pierce CB, Chandra M, Weiss R, Kaskel F, Council of Pediatric Nephrology and Urology, New York/New Jersey; Kidney and Urology Foundation of America (2007) The association of anemia and hypoalbuminemia with accelerated decline in GFR among adolescents with chronic kidney disease. Pediatr Nephrol 22:265–271PubMedGoogle Scholar
  21. 21.
    Wuhl E, Schaefer F (2008) Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol 23:705–716PubMedCentralPubMedGoogle Scholar
  22. 22.
    Filler G, Mylrea K, Feber J, Wong H (2007) How to define anemia in children with chronic kidney disease? Pediatr Nephrol 22:702–707PubMedGoogle Scholar
  23. 23.
    Amaral S, Hwang W, Fivush B, Neu A, Frankenfield D, Furth S (2006) Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. J Am Soc Nephrol 17:2878–2885PubMedGoogle Scholar
  24. 24.
    Warady BA, Ho M (2003) Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol 18:1055–1062PubMedGoogle Scholar
  25. 25.
    Maxwell PH, Ferguson DJ, Nicholls LG, Iredale JP, Pugh CW, Johnson MH, Ratcliffe PJ (1997) Sites of erythropoietin production. Kidney Int 51:393–401PubMedGoogle Scholar
  26. 26.
    Nangaku M, Eckardt KU (2007) Hypoxia and the HIF system in kidney disease. J Mol Med (Berl) 85:1325–1330Google Scholar
  27. 27.
    Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL (1996) Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 88:1576–1582PubMedGoogle Scholar
  28. 28.
    Pregi N, Wenker S, Vittori D, Leiros CP, Nesse A (2009) TNF-alpha-induced apoptosis is prevented by erythropoietin treatment on SH-SY5Y cells. Exp Cell Res 315:419–431PubMedGoogle Scholar
  29. 29.
    Yang B, Hosgood SA, Bagul A, Waller HL, Nicholson ML (2011) Erythropoietin regulates apoptosis inflammation and tissue remodelling via caspase-3 and IL-1ß in isolated hemoperfused kidneys. Eur J Pharmacol 660:420–430PubMedGoogle Scholar
  30. 30.
    Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, Badrawi SM, Lai P, Goldwasser E (1985) Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 82:7580–7584PubMedCentralPubMedGoogle Scholar
  31. 31.
    Sikole A, Spasovski G, Zafirov D, Polenakovic M (2002) Epoetin omega for treatment of anemia in maintenance hemodialysis patients. Clin Nephrol 57:237–245PubMedGoogle Scholar
  32. 32.
    Spinowitz BS, Pratt RD, Epoetin Delta 2002 Study Group (2006) Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. Curr Med Res Opin 22:25072513Google Scholar
  33. 33.
    United States Renal Data System (2009) USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, 2009 (available at
  34. 34.
    North American Pediatric Renal Trials and Collaborative Studies (2011) (NAPRTCS) 2011 Annual Dialysis Report (available at
  35. 35.
    Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290–299PubMedGoogle Scholar
  36. 36.
    Egrie JC, Browne JK (2001) Development and characterisation of novel erythropoiesis-stimulating protein (NESP). Nephrol Dial Transplant 16(Suppl 3):3–13PubMedGoogle Scholar
  37. 37.
    Debeljak N, Sytkowski AJ (2012) Erythropoietin and erythropoiesis-stimulating agents. Drug Test Anal 4:805–812PubMedGoogle Scholar
  38. 38.
    Warady BA, Arar MY, Lerner G, Nakanishi AM, Stehman-Breen C (2006) Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatr Nephrol 21:1144–1152PubMedGoogle Scholar
  39. 39.
    De Palo T, Giordano M, Palumbo F, Bellantuono R, Messina G, Colella V, Caringella AD (2004) Clinical experience with darbepoetin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 19:337–340PubMedGoogle Scholar
  40. 40.
    Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584–590PubMedGoogle Scholar
  41. 41.
    Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071–2084PubMedGoogle Scholar
  42. 42.
    Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098PubMedGoogle Scholar
  43. 43.
    Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032PubMedGoogle Scholar
  44. 44.
    Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL (2013) Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 61:44–56PubMedCentralPubMedGoogle Scholar
  45. 45.
    Kliger AS, Fishbane S, Finkelstein FO (2012) Erythropoietic-stimulating agents and quality of a patient’s life: individualizing anemia treatment. Clin J Am Soc Nephrol 7:354–357PubMedGoogle Scholar
  46. 46.
    Keithi-Reddy SR, Singh AK (2009) Hemoglobin target in chronic kidney disease: a pediatric perspective. Pediatr Nephrol 24:431–434PubMedGoogle Scholar
  47. 47.
    Koshy SM, Geary DF (2008) Anemia in children with chronic kidney disease. Pediatr Nephrol 23:209–219PubMedCentralPubMedGoogle Scholar
  48. 48.
    Foley RN (2008) Erythropoietin: physiology and molecular mechanisms. Heart Fail Rev 13:405–414PubMedGoogle Scholar
  49. 49.
    Port RE, Mehls O (2009) Erythropoietin dosing in children with chronic kidney disease: based on body size or on hemoglobin deficit? Pediatr Nephrol 24:435–437PubMedGoogle Scholar
  50. 50.
    Port RE, Kiepe D, Van Guilder M, Jelliffe RW, Mehls O (2004) Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage. Clin Pharmacokinet 43:57–70PubMedGoogle Scholar
  51. 51.
    Morris KP, Sharp J, Watson S, Coulthard MG (1993) Non-cardiac benefits of human recombinant erythropoietin in end-stage renal failure and anaemia. Arch Dis Child 69:580–586PubMedCentralPubMedGoogle Scholar
  52. 52.
    Jabs K (1996) The effects of recombinant human erythropoietin on growth and nutritional status. Pediatr Nephrol 10:324–327PubMedGoogle Scholar
  53. 53.
    Van Damme-Lombaerts R, Broyer M, Businger J, Baldauf C, Stocker H (1994) A study of recombinant human erythropoietin in the treatment of anemia of chronic renal failure in children on hemodialysis. Pediatr Nephrol 8:338–342PubMedGoogle Scholar
  54. 54.
    Yalcinkaya F, Tumer N, Cakar N, Ozkaya N (1997) Low-dose erythropoietin is effective and safe in children on continuous ambulatory peritoneal dialysis. Pediatr Nephrol 11:350–352PubMedGoogle Scholar
  55. 55.
    Gagnadoux MF, Loirat C, Berthélémé JP, Maisin A, Kamoun A, Dabout D, Poisson D, Broyer M (1994) Treatment of anemia in hemodialyzed children using recombinant human erythropoietin (Eprex). Results of a French multicenter clinical trial. Nephrologie 15:207–211PubMedGoogle Scholar
  56. 56.
    Chavers BM, Roberts TL, Herzog CA, Collins AJ, St Peter WL (2004) Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. Kidney Int 65:266–273PubMedGoogle Scholar
  57. 57.
    van Stralen KJ, Krischock L, Schaefer F, Verrina E, Groothoff JW, Evans J, Heaf J, Ivanov D, Kostic M, Maringhini S, Podracka L, Printza N, Pundziene B, Reusz GS, Vondrak K, Jager KJ, Tizard EJ, ESPN/ERA-EDTA Registry (2012) Prevalence and predictors of the sub-target Hb level in children on dialysis. Nephrol Dial Transplant 27:3950–3957PubMedGoogle Scholar
  58. 58.
    Opelz G, Graver B, Mickey MR, Terasaki PI (1981) Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients. Transplantation 32:177–183PubMedGoogle Scholar
  59. 59.
    Opelz G, Vanrenterghem Y, Kirste G, Gray DW, Horsburgh T, Lachance JG, Largiader F, Lange H, Vujaklija-Stipanovic K, Alvarez-Grande J, Schott W, Hoyer J, Schnuelle P, Descoeudres C, Ruder H, Wujciak T, Schwarz V (1997) Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 63:964–967PubMedGoogle Scholar
  60. 60.
    Sinai-Trieman L, Salusky IB, Fine RN (1989) Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis. J Pediatr 114:550–554PubMedGoogle Scholar
  61. 61.
    Kokot F, Wiecek A, Grzeszczak W (1991) Decreased need for blood transfusion during one year after discontinued erythropoietin treatment in haemodialyzed patients. Nephron 58:246–247PubMedGoogle Scholar
  62. 62.
    Grimm PC, Sinai-Trieman L, Sekiya NM, Robertson LS, Robinson BJ, Fine RN, Ettenger RB (1990) Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 38:12–18PubMedGoogle Scholar
  63. 63.
    Berland Y, Baz M, Di Stefano D, Merzouk T, Bartoli JM, Dussol B, Kasbarian M (1992) Recombinant human erythropoietin treatment reverses hepatic iron overload in hemodialysis patients. Nephrol Dial Transplant 7:366–367PubMedGoogle Scholar
  64. 64.
    Warady BA, Sabath RJ, Smith CA, Alon U, Hellerstein S (1991) Recombinant human erythropoietin in pediatric patients receiving long-term peritoneal dialysis. Pediatr Nephrol 5:718–723PubMedGoogle Scholar
  65. 65.
    Burke JR (1995) Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure. Australian and New Zealand Paediatric Nephrology Association. Pediatr Nephrol 9:558–561PubMedGoogle Scholar
  66. 66.
    Montini G, Zacchello G, Baraldi E, Zanconato S, Suppiej A, Fabris F, Andreetta B, Pavanello L, Zacchello F (1990) Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis. J Pediatr 117:556–560PubMedGoogle Scholar
  67. 67.
    Bamgbola OF (2011) Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int 80:464–474PubMedGoogle Scholar
  68. 68.
    Kalantar-Zadeh K, Höffken B, Wünsch H, Fink H, Kleiner M, Luft FC (1995) Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26:292–299PubMedGoogle Scholar
  69. 69.
    Warady BA, Kausz A, Lerner G, Brewer ED, Chadha V, Brugnara C, Dahl NV, Watkins SL (2004) Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 19:655–661PubMedGoogle Scholar
  70. 70.
    Warady BA, Zobrist RH, Wu J, Finan E, Ferrlecit Pediatric Study Group (2005) Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol 20:1320–1327PubMedGoogle Scholar
  71. 71.
    Goldstein S, Morris D, Warady BA (2013) Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial. Am J Kidney Dis 61:588–597PubMedGoogle Scholar
  72. 72.
    Young B, Zaritsky J (2009) Hepcidin for clinicians. Clin J Am Soc Nephrol 4:1384–1387PubMedGoogle Scholar
  73. 73.
    Atkinson MA, White CT (2012) Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist. Pediatr Nephrol 27:33–40PubMedGoogle Scholar
  74. 74.
    Bamgbola O (2012) Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations. Pediatr Nephrol 27:195–205PubMedGoogle Scholar
  75. 75.
    Macdougall I, Cooper A (2002) Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17:S39–S43Google Scholar
  76. 76.
    Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, Kovesdy CP, Kalantar-Zedeh K (2012) Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant. doi: 10.1093/ndt/gfs368 PubMedCentralPubMedGoogle Scholar
  77. 77.
    Gallieni M, Corsi C, Brancaccio D (2000) Hyperparathyroidism and anemia in renal failure. Am J Nephrol 20:89–96PubMedGoogle Scholar
  78. 78.
    Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB (2006) Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialyzed patients? Nephrology 11:394–399PubMedGoogle Scholar
  79. 79.
    Bamgbola OF, Kaskel F (2005) Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis. Pediatr Nephrol 20:1622–1629PubMedGoogle Scholar
  80. 80.
    Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P (2002) Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Eng J Med 346:469–475Google Scholar
  81. 81.
    Macdougall IC, Roger SD, de Francisco A, Goldsmith DJ, Schellekens H, Ebbers H, Jelkmann W, London G, Casadevall N, Hörl WH, Kemeny DM, Pollock C (2012) Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int 81:727–732PubMedGoogle Scholar
  82. 82.
    Mattison P, Upadhyay K, Wilcox JE, Moudgil A, Silverstein DM (2010) Anti-erythropoietin antibodies followed by endogenous erythropoietin production in a dialysis patient. Pediatr Nephrol 25:971–976PubMedGoogle Scholar
  83. 83.
    Cournoyer D, Toffelmire EB, Wells GA, Barber DL, Barrett BJ, Delage R, Forrest DL, Gagnon RF, Harvey EA, Laneuville P, Patterson BJ, Poon MC, Posen GA, Messner HA, Canadian PRCA Focus Group (2004) Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 15:2728–2734PubMedGoogle Scholar
  84. 84.
    Shimizu H, Saitoh T, Ota F, Jimbo T, Tsukada Y, Murakami H, Nojima Y (2011) Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol 126:114–118PubMedGoogle Scholar
  85. 85.
    Verhelst D, Rossert J, Casadevall N, Krüger A, Eckardt KU, Macdougall IC (2004) Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 363:1768–1771PubMedGoogle Scholar
  86. 86.
    Andrade J, Taylor PA, Love JM, Levin A (2005) Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone. Nephrol Dial Transplant 20:2548–2551PubMedGoogle Scholar
  87. 87.
    Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU (2009) A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 361:1848–1855PubMedGoogle Scholar
  88. 88.
    Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF (2010) Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153:23–33PubMedGoogle Scholar
  89. 89.
    Brandt JR, Avner ED, Hickman RO, Watkins SL (1999) Safety and efficacy of erythropoietin in children with chronic renal failure. Pediatr Nephrol 13:143–147PubMedGoogle Scholar
  90. 90.
    Coyne DW (2012) The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 82:235–241PubMedCentralPubMedGoogle Scholar
  91. 91.
    Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, Akizawa T, Pisoni RL, Port FK (2011) Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 22:358–365PubMedCentralPubMedGoogle Scholar
  92. 92.
    Chaknos CM, Berns JS (2013) Erythropoiesis-stimulating agents on trial: are higher dosages causing harm? Am J Kidney Dis 61:6–8PubMedGoogle Scholar
  93. 93.
    Smith KJ, Bleyer AJ, Little WC, Sane DC (2003) The cardiovascular effects of erythropoietin. Cardiovasc Res 59:538–548PubMedGoogle Scholar
  94. 94.
    Vaziri ND, Zhou XJ (2009) Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 24:1082–1088PubMedGoogle Scholar
  95. 95.
    Morakkabati N, Gollnick F, Meyer R, Fandrey J, Jelkmann W (1997) Erythropoietin induces Ca2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp Hematol 24:392–397Google Scholar
  96. 96.
    Covic A, Cannata-Andia J, Cancarini G, Coppo R, Frazão JM, Goldsmith D, Ronco P, Spasovski GB, Stenvinkel P, Utas C, Wiecek A, Zoccali C, London G (2011) Biosimilars and biopharmaceuticals: what nephrologists need to know—a position paper by the ERA-EDTA Council. Nephrol Dial Transplant 23:3731–3737Google Scholar
  97. 97.
    Jelkmann W (2012) Biosimilar recombinant human erythropoietins (“epoetins”) and future erythropoiesis-stimulating treatments. Expert Opin Biol Ther 12:581–592PubMedGoogle Scholar
  98. 98.
    Wish JB (2011) Erythropoiesis-stimulating agents and pure red-cell aplasia: you can’t fool Mother Nature. Kidney Int 80:11–13PubMedGoogle Scholar
  99. 99.
    Ahmed I (2011) Biosimilars in the US - Guidance from the European Experience. US Nephrol 6:84–90Google Scholar
  100. 100.
    Macdougall IC (2012) New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis 59:444–451PubMedGoogle Scholar
  101. 101.
    Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Jootar S, Intragumtornchai T, Tungsanga K, Teerapornlertratt T, Lumlertkul D, Townamchai N, Susantitaphong P, Katavetin P, Kanjanabuch T, Avihingsanon Y, Eiam-Ong S (2011) Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 80:88–92PubMedGoogle Scholar
  102. 102.
    Macdougall IC, Ashenden M (2009) Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chron Kidney Dis 16:117–130Google Scholar
  103. 103.
    Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273:458–464PubMedGoogle Scholar
  104. 104.
    Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, Green JM, Schatz PJ, Woodburn KW (2006) Preclinical evaluation of hematide, a novel erythropoiesis-stimulating agent, for the treatment of anemia. Exp Hematol 34:1303–1311PubMedGoogle Scholar
  105. 105.
    Del Vecchio L, Locatelli F (2011) New treatment approaches in chronic kidney disease-associated anemia. US Nephrol 6:91–94Google Scholar
  106. 106.
    Macdougall IC, Wiecek A, Tucker B, Yaqoob M, Mikhail A, Nowicki M, MacPhee I, Mysliwiec M, Smolenski O, Sułowicz W, Mayo M, Francisco C, Polu KR, Schatz PJ, Duliege AM (2011) Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol 6:2579–2586PubMedCentralPubMedGoogle Scholar
  107. 107.
    Locatelli F, Vecchio L (2011) New erythropoiesis-stimulating agents and new iron formulations. In: Ronco C, Rosner M (eds) Hemodialysis: New methods and future technology. Karger, Basel, pp 255–260Google Scholar
  108. 108.
    Fishbane S, Roger SD, Martin E, Runyan G, O’Neil J, Qiu P, Locatelli F (2012) Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa. Clin J Am Soc Nephrol 8:538–545PubMedCentralPubMedGoogle Scholar
  109. 109.
    Pérez-Ruixo JJ, Krzyzanski W, Bouman-Thio E, Miller B, Jang H, Bai SA, Zhou H, Yohrling J, Cohen A, Burggraaf J, Franson K, Davis HM (2009) Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects. Clin Pharmacokinet 48:601–613PubMedGoogle Scholar
  110. 110.
    Locatelli F, Villa G, de Francisco AL, Albertazzi A, Adrogue HJ, Dougherty FC, Beyer U, BA 16286 Study Investigators (2007) Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin 23:969–979PubMedGoogle Scholar
  111. 111.
    Cano F, Alarcon C, Azocar M, Lizama C, Maria Lillo A, Delucchi A, Gonzalez M, Arellano P, Delgado I, Droguett MT (2011) Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis. Pediatr Nephrol 26:1303–1310PubMedGoogle Scholar
  112. 112.
    Beuck S, Schanzer W, Thevis M (2012) Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Test Anal 4:830–845PubMedGoogle Scholar
  113. 113.
    Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Günzler V, Eckardt KU (2010) Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21:2151–2156PubMedCentralPubMedGoogle Scholar
  114. 114.
    Semenza GL, Wang GL (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447–5454PubMedCentralPubMedGoogle Scholar
  115. 115.
    Brill-Almon E, Stern B, Afik D, Kaye J, Langer N, Bellomo S, Shavit M, Pearlman A, Lippin Y, Panet A, Shani N (2005) Ex vivo transduction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins. Mol Ther 12:274–282PubMedGoogle Scholar
  116. 116.
    Wang G, Liu LN, Lee K, Buyaner D, Hendricks K, Kalfoglou CS, Bohnlein E, Junker U, Mosca JD (2009) Comparison of drug and cell-based delivery-engineering adult mesenchymal stem cells to deliver human erythropoietin. Gene Ther Mol Biol 13:321–330Google Scholar
  117. 117.
    Joung CH, Shin JY, Koo JK, Lim JJ, Wang JS, Lee SJ, Tan HK, Kim SL, Lim SM (2009) Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell. Protein Expr Purif 68:137–145PubMedGoogle Scholar
  118. 118.
    Schriebl K, Trummer E, Lattenmayer C, Weik R, Kunert R, Müller D, Katinger H, Vorauer-Uhl K (2006) Biochemical characterization of rhEPO-Fc fusion protein expressed in CHO cells. Protein Expr Purif 49:265–275PubMedGoogle Scholar
  119. 119.
    Ingley E, Tilbrook PA, Klinken SP (2004) New insights into the regulation of erythroid cells. IUBMB Life 56:177–184PubMedGoogle Scholar
  120. 120.
    Nakano Y, Imagawa S, Matsumoto K, Stockmann C, Obara N, Suzuki N, Doi T, Kodama T, Takahashi S, Nagasawa T, Yamamoto M (2004) Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood 104:4300–4351PubMedGoogle Scholar
  121. 121.
    Angelillo-Scherrer A, Burnier L, Lambrechts D, Fish RJ, Tjwa M, Plaisance S, Sugamele R, DeMol M, Martinez-Soria E, Maxwell PH, Lemke G, Goff SP, Matsushima GK, Earp HS, Chanson M, Collen D, Izui S, Schapira M, Conway EM, Carmeliet P (2008) Role of Gas6 in erythropoiesis and anemia in mice. J Clin Invest 118:583–596PubMedCentralPubMedGoogle Scholar
  122. 122.
    Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, Winters A, Juan T, Li H, Begley CG, Molineux G (2010) Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 115:3616–3624PubMedGoogle Scholar
  123. 123.
    Spaninger K, Debeljak N (2009) Erythropoietin, epoetins and detection. Pharm J Slov 60:279Google Scholar
  124. 124.
    Akebia Therapeutics Inc (2011) Akebia announces positive results for AKB-6548 phase 1 clinical study. Ref Type: Internet CommunicationGoogle Scholar
  125. 125.
    Bayer Healthcare (2011) Single dose group stratified study in renal impaired and healthy aged and gender matched subjects. Ref Type: Internet CommunicationGoogle Scholar

Copyright information

© IPNA 2013

Authors and Affiliations

  1. 1.Office of Device Evaluation, Renal Devices Branch (RNDB)United States Food and Drug AdministrationSilver SpringsUSA
  2. 2.Children’s Mercy Hospitals and ClinicsKansas CityUSA

Personalised recommendations